CNBC May 2, 2024
Key Points
– Moderna posted a narrower-than-expected loss for the first quarter as the company’s cost-cutting efforts took hold and sales of its Covid vaccine topped estimates.
– The results come as Moderna inches closer to having another product on the market, which it badly needs as demand for its Covid shots plunges worldwide.
– The company reiterated its full-year 2024 sales guidance of roughly $4 billion, which includes revenue from the expected launch of its RSV vaccine.
Moderna on Thursday posted a narrower-than-expected loss for the first quarter as the company’s cost-cutting efforts took hold and sales of its Covid vaccine, its only commercially available product, topped estimates.
The results come as Moderna inches closer to putting...
Today's Sponsors
Today's Sponsor